D.E. Shaw & Co
IMCR icon

D.E. Shaw & Co’s Immunocore IMCR Stock Holding History

D.E. Shaw & Co’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
405,116
+69,925
+21% +$2.07M 0.01% 1619
2026
Q1 		$10.1M Buy
335,191
+151,251
+82% +$4.89M 0.01% 1636
2025
Q4 		$6.38M Buy
+183,940
New +$6.49M ﹤0.01% 2106
2024
Q3 		– Sell
-19,515
Closed -$661K – 4692
2024
Q2 		$661K Sell
19,515
-120,579
-86% -$6.15M ﹤0.01% 3452
2024
Q1 		$9.11M Buy
140,094
+55,441
+65% +$3.8M 0.01% 1435
2023
Q4 		$5.78M Sell
84,653
-53,750
-39% -$2.79M 0.01% 1796
2023
Q3 		$7.18M Sell
138,403
-81,556
-37% -$4.83M 0.01% 1512
2023
Q2 		$13.2M Sell
219,959
-94,480
-30% -$5.39M 0.01% 1127
2023
Q1 		$15.5M Sell
314,439
-48,960
-13% -$2.75M 0.02% 1051
2022
Q4 		$20.7M Buy
363,399
+230,897
+174% +$13M 0.02% 891
2022
Q3 		$6.22M Buy
+132,502
New +$6.31M 0.01% 1838

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

D.E. Shaw & Co's IMCR Position: Q2 2026 in Review

D.E. Shaw & Co increased its Immunocore (IMCR) stake by 21% in Q2 2026, buying an estimated $2.07M and bringing the position to 405,116 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #1619.

D.E. Shaw & Co first reported a position in IMCR in Q3 2022 and has held it in 11 quarters since. The position peaked at $20.7M in Q4 2022. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • D.E. Shaw & Co held 405,116 shares of Immunocore worth $12.9M as of Q2 2026.
  • D.E. Shaw & Co bought 69,925 Immunocore shares in Q2 2026, an estimated $2.07M.
  • Immunocore made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1619 holding.
  • D.E. Shaw & Co first reported a position in Immunocore in Q3 2022 and has held it in 11 quarters since.
  • D.E. Shaw & Co's Immunocore position peaked at $20.7M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.